SS
URGN icon

SBI Securities’s UroGen Pharma URGN Stock Holding History

SBI Securities’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221 Sell
6
-14
-70% -$379 ﹤0.01% 3296
2026
Q1 		$360 Buy
20
+2
+11% +$40 ﹤0.01% 3014
2025
Q4 		$422 Sell
18
-29
-62% -$629 ﹤0.01% 2934
2025
Q3 		$938 Sell
47
-31
-40% -$557 ﹤0.01% 2719
2025
Q2 		$1.07K Buy
78
+11
+16% +$106 ﹤0.01% 2651
2025
Q1 		$741 Hold
67
– – ﹤0.01% 2717
2024
Q4 		$714 Buy
+67
New +$802 ﹤0.01% 2755

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SBI Securities's URGN Position: Q2 2026 in Review

SBI Securities reduced its UroGen Pharma (URGN) stake by 70% in Q2 2026, selling an estimated $379 and leaving 6 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #3296.

SBI Securities first reported a position in URGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.07K in Q2 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • SBI Securities held 6 shares of UroGen Pharma worth $221 as of Q2 2026.
  • SBI Securities sold 14 UroGen Pharma shares in Q2 2026, an estimated $379.
  • UroGen Pharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3296 holding.
  • SBI Securities first reported a position in UroGen Pharma in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's UroGen Pharma position peaked at $1.07K in Q2 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.